MX2013013384A - Metodo para tratamiento de cancer de pulmon de celulas no pequeñas. - Google Patents

Metodo para tratamiento de cancer de pulmon de celulas no pequeñas.

Info

Publication number
MX2013013384A
MX2013013384A MX2013013384A MX2013013384A MX2013013384A MX 2013013384 A MX2013013384 A MX 2013013384A MX 2013013384 A MX2013013384 A MX 2013013384A MX 2013013384 A MX2013013384 A MX 2013013384A MX 2013013384 A MX2013013384 A MX 2013013384A
Authority
MX
Mexico
Prior art keywords
lung cancer
cell lung
small cell
nucleotides
treating non
Prior art date
Application number
MX2013013384A
Other languages
English (en)
Inventor
Martin Gleave
Chen Duksin
Shoshi Tessler
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47177396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013013384(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2013013384A publication Critical patent/MX2013013384A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un método de tratamiento de un paciente humano que padece de cáncer de pulmón que comprende administrar periódicamente al paciente humano quimioterapia que consiste en una cantidad de taxano y 640 mg de un oligonucleótido anti-clusterina que tiene la secuencia CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), en donde el oligonucleótido anti-clusterina tiene una columna de fosforotioato a lo largo, tiene porciones de azúcar de los nucleótidos 1-4 y 18-21 que llevan modificaciones de 2´-O-metoxietilo, tiene nucleótidos 5-17 los cuales son 2'desoxinucleótidos, y tiene 5-metilcitosinas en los nucleótidos 1, 4, y 19, con lo cual se trata al paciente humano que padece de cáncer de pulmón de células no pequeñas.
MX2013013384A 2011-05-19 2012-05-18 Metodo para tratamiento de cancer de pulmon de celulas no pequeñas. MX2013013384A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161487918P 2011-05-19 2011-05-19
US201161493346P 2011-06-03 2011-06-03
PCT/IB2012/001085 WO2012156817A2 (en) 2011-05-19 2012-05-18 Method for treating non-small cell lung cancer

Publications (1)

Publication Number Publication Date
MX2013013384A true MX2013013384A (es) 2014-06-11

Family

ID=47177396

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013384A MX2013013384A (es) 2011-05-19 2012-05-18 Metodo para tratamiento de cancer de pulmon de celulas no pequeñas.

Country Status (16)

Country Link
US (1) US20130017272A1 (es)
EP (1) EP2709673A4 (es)
JP (1) JP2014520081A (es)
KR (1) KR20140034838A (es)
CN (1) CN103958681A (es)
AR (1) AR086514A1 (es)
AU (1) AU2012257487A1 (es)
CA (1) CA2836676A1 (es)
CL (1) CL2013003324A1 (es)
EA (1) EA201391725A1 (es)
IL (1) IL227720A0 (es)
MX (1) MX2013013384A (es)
PE (1) PE20140647A1 (es)
SG (1) SG194931A1 (es)
WO (1) WO2012156817A2 (es)
ZA (1) ZA201309254B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2850318A1 (en) 1999-02-26 2000-08-31 The University Of British Columbia Trpm-2 antisense therapy
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
CA2830195A1 (en) 2011-03-15 2012-09-20 Martin E. Gleave Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer
UY34812A (es) * 2012-05-18 2013-12-31 Teva Pharma Método para el tratamiento del cáncer de pulmón de células no pequeñas
CA2903239A1 (en) * 2013-03-14 2014-10-02 Oncogenex Technologies Inc. Custirsen treatment with reduced toxicity
CA2900533A1 (en) * 2013-03-14 2014-10-02 Oncogenex Technologies Inc. Anti-clusterin monotherapy for cancer treatment
US20160324439A1 (en) * 2015-05-06 2016-11-10 Taiwan Textile Research Institute Stereoscopic conductive fabric and module for detecting electrical signals from body skin applying the same
WO2016191751A1 (en) * 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
AU2016270782B2 (en) * 2015-05-29 2021-08-12 Dynavax Technologies Corporation Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung
KR20190115505A (ko) 2018-03-15 2019-10-14 특허법인 해담 기업 맞춤형 후속 개발 아이템 발굴 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
HU229452B1 (en) * 2002-01-17 2013-12-30 Univ British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
WO2005094899A1 (en) * 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
US7348391B2 (en) * 2004-09-02 2008-03-25 Isis Pharmaceuticals, Inc. Polymeric beads for oligomer synthesis

Also Published As

Publication number Publication date
AR086514A1 (es) 2013-12-18
EA201391725A1 (ru) 2014-05-30
KR20140034838A (ko) 2014-03-20
PE20140647A1 (es) 2014-06-05
WO2012156817A3 (en) 2013-02-21
AU2012257487A1 (en) 2014-01-16
JP2014520081A (ja) 2014-08-21
ZA201309254B (en) 2015-05-27
IL227720A0 (en) 2013-09-30
EP2709673A2 (en) 2014-03-26
CL2013003324A1 (es) 2014-08-01
WO2012156817A9 (en) 2013-01-03
SG194931A1 (en) 2013-12-30
WO2012156817A2 (en) 2012-11-22
CN103958681A (zh) 2014-07-30
EP2709673A4 (en) 2014-12-17
US20130017272A1 (en) 2013-01-17
CA2836676A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
PH12014502569A1 (en) Method for treating non-small cell lung cancer
MX2013013384A (es) Metodo para tratamiento de cancer de pulmon de celulas no pequeñas.
NZ599032A (en) Modulation of huntingtin expression
HRP20210612T1 (hr) Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk
JP2012228254A5 (es)
NZ563845A (en) RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic
NZ716534A (en) Antisense molecules and methods for treating pathologies
NZ715081A (en) Antisense oligomers and conjugates targeting pcsk9
MX359548B (es) Agentes de iarn modificados.
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
NZ592867A (en) Compositions and methods for inhibiting expression of transthyretin
NZ593618A (en) Gnaq targeted dsrna compositions and methods for inhibiting expression
NZ630596A (en) Methods for treatment of alport syndrome
WO2013090457A3 (en) In vivo delivery of oligonucleotides
SG170780A1 (en) Compositions and methods for inhibiting expression of eg5 gene
WO2009058907A3 (en) Targeting micrornas for the treatment of liver cancer
MX2013009191A (es) Oligonucleotidos antisentido.
JP2013529909A5 (es)
MX2013005875A (es) Inhibidores de microarn que comprenden nucleotidos bloqueados.
TN2015000079A1 (en) Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
BR112013002738A2 (pt) métodos e compostos para o diagnóstico e o tratamento do câncer
Staedel et al. Inhibition of gastric tumor cell growth using seed-targeting LNA as specific, long-lasting MicroRNA inhibitors
WO2007117121A3 (en) Gene therapy for cancer using small interfering rna specific to ant2 and a method to overcome tolerance to antitumor agent
IN2014CN03921A (es)
MX348555B (es) Agente preventivo o terapeutico contra la fibrosis.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal